Sino Biopharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	12,181	9,570	9,452	12,066	10,569
Short-Term Investments	-	220.64	1,553	-	569.5
Trading Asset Securities	10,366	5,028	3,113	4,855	4,656
Cash & Short-Term Investments	22,547	14,818	14,118	16,922	15,794
Cash Growth	52.16%	4.96%	-16.57%	7.14%	-3.88%
Accounts Receivable	6,264	5,013	4,596	4,643	4,285
Other Receivables	376.4	1,787	1,602	1,575	1,164
Receivables	6,640	6,800	6,199	6,219	5,537
Inventory	2,257	2,373	1,993	2,329	1,938
Prepaid Expenses	3,022	694.17	582.57	465.69	234.13
Other Current Assets	-	-	912.71	-	-
Total Current Assets	34,465	24,685	23,806	25,935	23,503
Property, Plant & Equipment	10,233	10,288	9,912	9,251	8,516
Long-Term Investments	23,465	26,337	25,181	25,230	25,169
Goodwill	3,496	915.69	680.45	662.61	647.93
Other Intangible Assets	3,556	271.89	248.49	278.35	291.56
Long-Term Deferred Tax Assets	506.59	516.29	567.01	505.15	334.87
Long-Term Deferred Charges	-	1,873	1,980	973.49	772.46
Other Long-Term Assets	287.51	520.8	1,230	1,229	1,308
Total Assets	76,010	65,408	63,605	64,064	60,543
Accounts Payable	1,497	1,497	1,335	1,884	1,795
Accrued Expenses	-	7,651	6,716	6,299	5,146
Short-Term Debt	-	-	136.13	136.13	136.13
Current Portion of Long-Term Debt	8,395	7,602	11,136	9,663	6,521
Current Portion of Leases	23.29	28.33	71.49	60.43	64.47
Current Income Taxes Payable	696.15	318.2	271.87	107.46	101.17
Current Unearned Revenue	-	253.24	282.6	310.79	238.2
Other Current Liabilities	14,587	2,206	2,658	1,690	1,344
Total Current Liabilities	25,200	19,556	22,607	20,151	15,345
Long-Term Debt	7,584	1,997	1,074	3,934	5,213
Long-Term Leases	67.31	83.39	298.39	324.26	319.95
Long-Term Unearned Revenue	621.88	557.92	548.27	749.07	674.45
Long-Term Deferred Tax Liabilities	286.4	237.55	781.54	831.79	881.59
Other Long-Term Liabilities	164.76	201.9	125.46	131.08	380.78
Total Liabilities	33,924	22,634	25,435	26,121	22,814
Common Stock	413.67	414.38	414.62	414.9	415.44
Additional Paid-In Capital	-	12,421	12,443	12,484	12,578
Retained Earnings	-	25,281	23,649	28,358	27,215
Treasury Stock	-2,951	-2,975	-1,770	-1,432	-689.35
Comprehensive Income & Other	33,209	-3,180	-4,262	-10,078	-9,228
Total Common Equity	30,671	31,961	30,474	29,747	30,291
Minority Interest	11,415	10,813	7,695	8,197	7,438
Shareholders' Equity	42,086	42,774	38,170	37,944	37,729
Total Liabilities & Equity	76,010	65,408	63,605	64,064	60,543
Total Debt	16,070	9,711	12,716	14,118	12,254
Net Cash (Debt)	6,477	5,107	1,402	2,804	3,540
Net Cash Growth	26.81%	264.34%	-50.00%	-20.81%	59.33%
Net Cash Per Share	0.36	0.28	0.08	0.15	0.18
Filing Date Shares Outstanding	17,892	17,924	18,347	18,468	18,699
Total Common Shares Outstanding	17,892	17,924	18,347	18,468	18,699
Working Capital	9,266	5,129	1,199	5,784	8,158
Book Value Per Share	1.71	1.78	1.66	1.61	1.62
Tangible Book Value	23,619	30,773	29,546	28,806	29,352
Tangible Book Value Per Share	1.32	1.72	1.61	1.56	1.57
Buildings	-	5,016	4,248	3,871	3,571
Machinery	-	8,433	7,628	6,692	6,132
Construction In Progress	-	1,701	1,686	1,804	1,426

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.